Galapagos NV GLPG
Morningstar Growth Grade = A
Projected Annual Return = 19.6%
June 22, 2021 price = $73.50
Company Profile
Business Description
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
SectorHealthcare
IndustryBiotechnology
Most Recent EarningsMar 31, 2021
Fiscal Year EndDec 31, 2021
Stock Type—
Employees1,328
No comments:
Post a Comment